Al-kuraishy HM, Fahad EH, Al-Windy S et al (2024) The effects of cholesterol and statins on Parkinson’s neuropathology: a narrative review. Inflammopharmacol 32:917–925. https://doi.org/10.1007/s10787-023-01400-z

Article  Google Scholar 

Bar-On P, Crews L, Koob AO et al (2008) Statins reduce neuronal α-synuclein aggregation in in vitro models of Parkinson’s disease. J Neurochem 105:1656–1667. https://doi.org/10.1111/j.1471-4159.2008.05254.x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barton AR, Sherman MA, Mukamel RE, Loh P-R (2021) Whole-exome imputation within UK biobank powers rare coding variant association and fine-mapping analyses. Nat Genet 53:1260–1269. https://doi.org/10.1038/s41588-021-00892-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheng KK, Swallow DM, Grosset KA, Grosset DG (2017) Statin usage, vascular diagnosis and vascular risk factors in Parkinson’s disease. Scott Med J 62:104–109. https://doi.org/10.1177/0036933017727432

Article  PubMed  Google Scholar 

Consortium GLG (2013) Discovery and refinement of loci associated with lipid levels. Nat Genet 45:1274–1283. https://doi.org/10.1038/ng.2797

Article  CAS  Google Scholar 

D’Agostino RB, Vasan RS, Pencina MJ et al (2008) General cardiovascular risk profile for use in primary care. Circulation 117:743–753. https://doi.org/10.1161/circulationaha.107.699579

Article  PubMed  Google Scholar 

Diaz-Ortiz ME, Seo Y, Posavi M et al (2022) GPNMB confers risk for Parkinson’s disease through interaction with α-synuclein. Science. https://doi.org/10.1126/science.abk0637

Article  PubMed  PubMed Central  Google Scholar 

Dijkstra AA, Ingrassia A, de Menezes RX et al (2015) Evidence for immune response, axonal dysfunction and reduced endocytosis in the substantia nigra in early stage Parkinson’s disease. PLoS One 10:e0128651–e0128651. https://doi.org/10.1371/journal.pone.0128651

Article  CAS  Google Scholar 

Emdin CA, Khera AV, Kathiresan S (2017) Mendelian randomization. JAMA 318:1925–1925. https://doi.org/10.1001/jama.2017.17219

Article  PubMed  Google Scholar 

German CA, Liao JK (2023) Understanding the molecular mechanisms of statin pleiotropic effects. Arch Toxicol 97:1529–1545. https://doi.org/10.1007/s00204-023-03492-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giambartolomei C, Vukcevic D, Schadt EE et al (2014) Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet 10:e1004383. https://doi.org/10.1371/journal.pgen.1004383

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goswami D, Anuradha U, Angati A et al (2022) Pharmacological and pathological relevance of S100 proteins in neurological disorders. CNS Neurol Disord Drug Targets 22:1403–1416. https://doi.org/10.2174/1871527322666221128160653

Article  CAS  Google Scholar 

Grundy SM, Stone NJ, Bailey AL (2018) 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (2018) A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 139. https://doi.org/10.1161/cir.0000000000000625

Hippisley-Cox J, Coupland C (2010) Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 340:c2197–c2197. https://doi.org/10.1136/bmj.c2197

Article  Google Scholar 

Iwaki H, Blauwendraat C, Leonard HL et al (2019) Genomewide association study of Parkinson’s disease clinical biomarkers in 12 longitudinal patients’ cohorts. Mov Disord 34:1839–1850. https://doi.org/10.1002/mds.27845

Article  PubMed  PubMed Central  Google Scholar 

Jeong S, Jang W, Shin DW (2019) Association of statin use with parkinson’s disease: dose–response relationship. Mov Disord 34:1014–1021. https://doi.org/10.1002/mds.27681

Article  CAS  PubMed  Google Scholar 

Jeong SH, Lee HS, Chung SJ et al (2021) Effects of statins on dopamine loss and prognosis in Parkinson’s disease. Brain 144:3191–3200. https://doi.org/10.1093/brain/awab292

Article  PubMed  Google Scholar 

Lewis MM, Albertson RM, Du G et al (2022) Parkinson’s disease progression and statins: hydrophobicity matters. J Parkinsons Dis 12:821–830. https://doi.org/10.3233/jpd-212819

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu G, Sterling NW, Kong L et al (2017) Statins may facilitate Parkinson’s disease: insight gained from a large, national claims database. Mov Disord 32:913–917. https://doi.org/10.1002/mds.27006

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lu D, Shen L, Mai H et al (2019) HMG-CoA reductase inhibitors attenuate neuronal damage by suppressing oxygen glucose Deprivation-Induced activated microglial cells. Neural Plast 2019:1–15. https://doi.org/10.1155/2019/7675496

Article  CAS  Google Scholar 

Mach F, Baigent C, Catapano AL et al (2019) 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis 290:140–205. https://doi.org/10.1016/j.atherosclerosis.2019.08.014

Article  CAS  Google Scholar 

Marek K, Jennings D, Lasch S et al (2011) The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 95:629–635. https://doi.org/10.1016/j.pneurobio.2011.09.005

Article  Google Scholar 

Nikpay M, Goel A, Won H-H et al (2015) A comprehensive 1000 Genomes–based genome-wide association meta-analysis of coronary artery disease. Nat Genet 47:1121–1130. https://doi.org/10.1038/ng.3396

Article  CAS  PubMed  PubMed Central  Google Scholar 

Palermo G, Giannoni S, Giuntini M et al (2021) Statins in Parkinson’s disease: influence on motor progression. JPD 11:1651–1662. https://doi.org/10.3233/jpd-212655

Article  CAS  PubMed  Google Scholar 

Pigott K, Rick J, Xie SX et al (2015) Longitudinal study of normal cognition in Parkinson disease. Neurology 85:1276–1282. https://doi.org/10.1212/wnl.0000000000002001

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roy A, Pahan K (2011) Prospects of statins in Parkinson disease. Neuroscientist 17:244–255. https://doi.org/10.1177/1073858410385006

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rubio-Osornio M, León CTG-D, Montes S et al (2023) Repurposing Simvastatin in parkinson’s disease model: protection is throughout modulation of the Neuro-Inflammatory response in the substantia Nigra. IJMS 24:10414. https://doi.org/10.3390/ijms241310414

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schrag A, Siddiqui UF, Anastasiou Z et al (2016) Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed parkinson’s disease: a cohort study. Lancet Neurol 16:66–75. https://doi.org/10.1016/s1474-4422(16)30328-3

Article  PubMed  PubMed Central  Google Scholar 

Stevens K, Creanor S, Jeffery AN et al (2022) Evaluation of Simvastatin as a disease-Modifying treatment for patients with Parkinson disease A randomized clinical trial

Tan W, Xue-bin C, Tian Z et al (2015) Effects of simvastatin on the expression of inducible nitric oxide synthase and brain-derived neurotrophic factor in a lipopolysaccharide-induced rat model of Parkinson disease. Int J Neurosci 126:278–286. https://doi.org/10.3109/00207454.2015.1012758

Article  CAS  PubMed  Google Scholar 

Verbanck M, Chen C-Y, Neale B, Do R (2018) Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet 50:693–698. https://doi.org/10.1038/s41588-018-0099-7

Article  CAS  PubMed